Dhiraj Carumbaya joins concertAl asSenior Vice President and GeneralManager of TeraRecon
by TeraRecon, on May 16, 2024 6:35:00 AM
CAMBRIDGE, Mass., May.16, 2024/PRNewswire/-ConcertAl, the leader in oncologypredictive and generative Al SaaS Solutions and Real World Data for healthcare andlife sciences, today announced that Dhiraj Carumbaya has joined the
company asSenior Vice President and General Manager of the company's TeraRecon business.Dhiraj brings over two decades of domain and industry experience in MedicalImaging, Healthcare Informatics, and Clinical Al. He will lead
ConcertAl's industryleading advanced visualization solution Intuitiontm, leading in class Eurekatm ClinicalAl, a new product group focused on lmaging data solutions, and a new groupfocused on advanced Generative Al innovations for
imaging interpretation andclinical research applications.
“Dhirajstarted his career focused on Diagnostic lmaging and directly runninghealthcare provider solutions using Al - that was the key criterion we had for thisleadership role," said Jeff Elton, PhD, CEO of ConcertAl. “His depth in
imagingbroadly, SaaS technologies, and Al, he is uniquely suited to ensure our provider andbiopharma partners have the most advanced technologies and data to transformthe diagnostic and research experience. Over time, our
customers will seebenefits from the company's leading work in precision oncology, and our recentlyannounced CARAai platform and TereRecon imaging expertise come together toadvance evidence-based decision augmentations and
research solutions spanningtranslational sciences through clinical development".
Dhiraj started as a researcher in medical physics, progressed through healthcareproviders, and managed sizeable businesses at RadNet, Philips Healthcare, AmazonAWS, GE Healthcare, and Fujifilm. At Philips, he doubled the Radiology
Informaticsbusiness in two years. At AWS, he oversaw creating and scaling Amazon's next-generation cloud solutions for the healthcare and life sciences industries. Beforethat, he held global product and business leadership roles at GE
Healthcare. Dhirajhas also consulted for the US Government's Accountability Office in Healthcare IT.
"Infusion of generative Al in medical imaging to automate the segmentation ofbiomarkers, such as tumors from high-fidelity medical images and biologicaldiagnostics, is a transformative experience for the healthcare providers
andbiopharma industry," said Dhiraj,. “l am excited to lead the talented Terarecon teamas the company enters a new phase of growth by bringing true innovations to ourcustomers in medical diagnosis, clinical research, and drug
development."
About ConcertAl: ConcertAl is the leader in Predictive and Generative Al SaaS andReal-world Data research solutions and healthcare and life sciences. Our mission isto accelerate insights and outcomes for patients through research-ready
data,CARA Al technologies, and scientific expertise in partnership with the leadingbiomedical innovators, health care providers, and medical societies. Serving over1,900 clinical sites and 45 biomedical innovators ConcertAl companies and
solutionsare "Best in KLAS" and awarded the 2020, 2021, and 2022 KLAS recognition.CancerLinQ® is an Initiative of ConcertAl, providing oncology providers AsCOaligned automated QOPl quality solutions and SmartLinQ analytic
services.Headquartered in Cambridge, MA, ConcertAl has offices in Philadelphia, Frankfurt,Raleigh-Durham, and Tokyo. For more information, visit us at www.concertai.com.
About TeraRecon: Serving ~l,900 clinical sites globally, TeraRecon, a ConcertAlcompany, is a Best in KLAS solution provider for Al-empowered radiology, oncology,cardiology, neurology, and vascular surgery. Awarded the KLAS Category
Leader forAdvanced Visualization, TeraRecon solutions are independent of any onemanufacturer's imaging equipment or PACS system, allowing a single, unified, andsimplified clinical workflow that can improve efficiencies and deliver
actionablephysician-guided insights. For more information, visit us at www.terarecon.com